Inventor · disambiguated record
Alan P. Kaplan
Also filed as: KAPLAN ALAN · KAPLAN ALAN P
30 granted patents·12 pending applications·99 citations·filing 2000–2025
96Inventor score
Files withDART NEUROSCIENCE CAYMAN LTD16KAPLAN ALAN P7HELICON THERAPEUTICS INC5DART NEUROSCIENCE LLC3VIGIL NEUROSCIENCE INC3
Top patents by PatentIndex Score
42 records- 0191US8222243B2Therapeutic isoxazole compoundsKAPLAN ALAN P·Filed 2008·Granted Jul 17, 2012·8 cites·27 claims
- 0291US7829713B2Therapeutic piperazinesHELICON THERAPEUTICS INC·Filed 2007·Granted Nov 9, 2010·42 cites·3 claims
- 0387US9650349B2Therapeutic isoxazole compoundsDART NEUROSCIENCE (CAYMAN) LTD·Filed 2015·Granted May 16, 2017·3 cites·18 claims
- 0487US2025122172A1Substituted pyridine and pyrazine compounds as pde4 inhibitorsDART NEUROSCIENCE LLC·Filed 2024·Application pending·0 cites
- 0584US8338405B2Therapeutic piperazinesKEENAN TERENCE P·Filed 2010·Granted Dec 25, 2012·8 cites·16 claims
- 0683US8921399B2Therapeutic isoxazole compoundsKAPLAN ALAN P·Filed 2012·Granted Dec 30, 2014·2 cites·21 claims
- 0783US7872002B2Therapeutic pyrazoloquinoline derivativesHELICON THERAPEUTICS INC·Filed 2008·Granted Jan 18, 2011·6 cites·40 claims
- 0882US8277842B1Enteric-coated HT-2157 compositions and methods of their useKAPLAN ALAN P·Filed 2012·Granted Oct 2, 2012·5 cites·20 claims
- 0981US9120770B2Substituted pyridine and pyrazine compounds as PDE4 inhibitorsDART NEUROSCIENCE CAYMAN LTD·Filed 2014·Granted Sep 1, 2015·3 cites·30 claims
- 1080US7919626B2Pyrazole compounds and uses thereofHELICON THERAPEUTICS INC·Filed 2007·Granted Apr 5, 2011·4 cites·1 claims
- 1179US2023075774A1Substituted pyridine and pyrazine compounds as pde4 inhibitorsDART NEUROSCIENCE LLC·Filed 2022·Application pending·0 cites
- 1278US9040692B2Substituted pyridine and pyrazine compounds as PDE4 inhibitorsDART NEUROSCIENCE CAYMAN LTD·Filed 2014·Granted May 26, 2015·2 cites·1 claims
- 1377US9708334B2Substituted 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine compounds as GlyT1 inhibitorsDART NEUROSCIENCE (CAYMAN) LTD·Filed 2015·Granted Jul 18, 2017·2 cites·20 claims
- 1476US9150572B2Substituted naphthyridine and quinoline compounds as MAO inhibitorsDART NEUROSCIENCE CAYMAN LTD·Filed 2014·Granted Oct 6, 2015·2 cites·3 claims
- 1576US9102674B2Substituted naphthyridine and quinoline compounds as MAO inhibitorsDART NEUROSCIENCE CAYMAN LTD·Filed 2014·Granted Aug 11, 2015·2 cites·35 claims
- 1676US9029397B2Therapeutic isoxazole compoundsKAPLAN ALAN P·Filed 2012·Granted May 12, 2015·1 cites·44 claims
- 1776US7863266B2Therapeutic pyrazoloquinoline urea derivativesHELICON THERAPEUTICS INC·Filed 2008·Granted Jan 4, 2011·2 cites·46 claims
- 1876US7858614B2Therapeutic pyrazolonaphthyridine derivativesHELICON THERAPEUTICS INC·Filed 2008·Granted Dec 28, 2010·2 cites·26 claims
- 1974US9573937B2Substituted pyridine and pyrazine compounds as PDE4 inhibitorsDART NEUROSCIENCE (CAYMAN) LTD·Filed 2015·Granted Feb 21, 2017·1 cites·20 claims
- 2073US11279691B2Substituted pyridine and pyrazine compounds as PDE4 inhibitorsDART NEUROSCIENCE LLC·Filed 2019·Granted Mar 22, 2022·0 cites·4 claims
- 2172US9675605B2Substituted naphthyridine and quinoline compounds as MAO inhibitorsDART NEUROSCIENCE (CAYMAN) LTD·Filed 2015·Granted Jun 13, 2017·1 cites·7 claims
- 2269US8501745B2Piperazine PDE4 inhibitors and uses thereofKEENAN TERENCE P·Filed 2010·Granted Aug 6, 2013·1 cites·17 claims
- 2367US8791137B2Therapeutic compoundsZHOU XIANBO·Filed 2010·Granted Jul 29, 2014·1 cites·4 claims
- 2467US8399487B2Pyrazole compounds and uses thereofZHOU XIANBO·Filed 2010·Granted Mar 19, 2013·1 cites·27 claims
- 2567US2025042897A1Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of useVIGIL NEUROSCIENCE INC·Filed 2022·Application pending·0 cites
- 2665US2018346448A1Substituted pyridine and pyrazine compounds as pde4 inhibitorsDART NEUROSCIENCE CAYMAN LTD·Filed 2018·Application pending·0 cites
- 2764US10053467B2Therapeutic isoxazole compoundsDART NEUROSCIENCE CAYMAN LTD·Filed 2017·Granted Aug 21, 2018·0 cites·20 claims
- 2864US2016009691A1Substituted pyridine and pyrazine compounds as pde4 inhibitorsDART NEUROSCIENCE CAYMAN LTD·Filed 2014·Application pending·0 cites
- 2963US9624200B2Therapeutic piperazinesDART NEUROSCIENCE (CAYMAN) LTD·Filed 2014·Granted Apr 18, 2017·0 cites·21 claims
- 3060US2014038945A1Piperazine pde4 inhibitors and uses thereofDART NEUROSCIENCE CAYMAN LTD·Filed 2013·Application pending·0 cites
- 3159US9956213B2Substituted naphthyridine and quinoline compounds as MAO inhibitorsDART NEUROSCIENCE CAYMAN LTD·Filed 2017·Granted May 1, 2018·0 cites·18 claims
- 3259US2025304580A1Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of useVIGIL NEUROSCIENCE INC·Filed 2025·Application pending·0 cites
- 3356US2024309003A1Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of useVIGIL NEUROSCIENCE INC·Filed 2022·Application pending·0 cites
- 3453US8927546B2Therapeutic piperazinesKAPLAN ALAN P·Filed 2010·Granted Jan 6, 2015·0 cites·10 claims
- 3549US2013189314A1Enteric-coated ht-2157 compositions and methods of their useDART NEUROSCIENCE CAYMAN LTD·Filed 2012·Application pending·0 cites
- 3647US8343957B2Therapeutic pyrazoloquinoline urea derivativesDART NEUROSCIENCE CAYMAN LTD·Filed 2010·Granted Jan 1, 2013·0 cites·14 claims
- 3746US8598159B2Therapeutic pyrazoloquinoline derivativesKAPLAN ALAN P·Filed 2010·Granted Dec 3, 2013·0 cites·7 claims
- 3846US8497262B2Therapeutic pyrazolonaphthyridine derivativesKAPLAN ALAN P·Filed 2010·Granted Jul 30, 2013·0 cites·7 claims
- 3944US2006273819A1Antibiotic tetrahydro-beta-carboline derivativesOPPERMAN TIMOTHY·Filed 2004·Application pending·0 cites
- 4039US2007027190A1Antibacterial fab i inhibitorsMOIR DONALD T·Filed 2004·Application pending·0 cites
- 4135US9012470B2Therapeutic 5,6,5-tricyclic analogsGUPTA VARSHA·Filed 2011·Granted Apr 21, 2015·0 cites·12 claims
- 4233US2002052295A1Diacyl derivatives of propylene diamine having herbicidal activityFiled 2000·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →